- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02035488
Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis
Study Overview
Detailed Description
Rationale: Bronchiectasis is a persistent and frequently progressive condition characterized by dilated and thick-walled bronchi retaining sputum. The main symptoms of bronchiectasis are cough and chronic sputum production. There is a state of constant colonization with bacteria, which frequently causes exacerbations. The presence of Pseudomonas aeruginosa is an unfavorable prognostic indicator and is associated with increased sputum production, more extensive bronchiectasis on HR-CT of the thorax, more hospitalizations and reduced quality of life. Until now, most patients with non-CF bronchiectasis who are colonized with P. aeruginosa receive inhaled tobramycin every other month, by use of a nebulizer. However, this delivery system has several disadvantages, like a low lung deposition and pollution with tobramycin in the surrounding environment. With an efficient dry powder inhaler (DPI), a three to six fold higher lung deposition compared to a nebulizer can be obtained. Therapy with a DPI is also less time consuming compared to nebulisation. Nebulised tobramycin is used most in routine care; there is also one, rather poorly characterized DPI for tobramycin available, though this DPI is not registrered for non-CF bronchiectasis. We will investigate dry powder tobramycin (DP tobramycin) in a novel device in patients with non-CF bronchiectasis colonized with P. aeruginosa.
Objective: The main objectives are to investigate the pharmacokinetic properties of DP tobramycin at different dosages together with the local tolerability of DP tobramycin via the Cyclops® at different dosages.
Study design: single center, single ascending, single dose, response study. Study population: 8 patients with non-CF bronchiectasis
Main study parameters:
The following pharmacokinetic parameters will be calculated: actual dose (dose minus remainder in inhaler after inhalation), AUC0-12 (area under the curve from 0 -12 h), Cmax (maximum plasma concentration), Tmax (time to maximum plasma concentration), Ka (absorption rate constant), T1/2 el (terminal elimination half-life), CL/F (clearance following pulmonary administration (F= bioavailability)).
Local tolerability of DP tobramycin is determined by scoring adverse events, specifically coughing, and lung function measurement.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: All participants included in this study are patients recruited from the outpatient department of pulmonology. To investigate safety, lung function tests will be performed and the occurrence of adverse events will be scored.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Groningen, Netherlands
- University Medical Center Groningen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Age 18 years or older
- Obtained informed consent
- Patients having bronchiectasis (confirmed with HR-CT of the chest)
Exclusion criteria:
- Pregnant or breast feeding
- Subjects with known or suspected renal, auditory, vestibular or neuromuscular dysfunction, or with severe, active haemoptysis,
- History of adverse events on previous tobramycin or other aminoglycoside use
- No concurrent use of cyclosporin, cisplatin, amfotericin B, cephalosporins, polymyxins, vancomycin and NSAIDs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tobramycin
Patients with bronchiectasis
|
Tobramycin dry powder 30 mg inhalation per dose; Dose escalation: 30-60-120 and 240 mg, each one time.
One dose per week.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Actual dose (dose minus remainder in inhaler after inhalation) of tobramycin
Time Frame: one day
|
one day
|
Area Under the plasma concentration versus time curve from 0 -12 hours (AUC0-12) of tobramycin •Area Under the plasma concentration versus time curve from 0 -12 hours (AUC0-12) of tobramycin
Time Frame: One day
|
One day
|
Maximum plasma concentration (Cmax ) of tobramycin
Time Frame: One day
|
One day
|
Time to maximum plasma concentration (Tmax) of tobramycin
Time Frame: One day
|
One day
|
Absorption rate constant (Ka) of tobramycin
Time Frame: One day
|
One day
|
Terminal elimination half-life (T1/2 el ) of tobramycin
Time Frame: One day
|
One day
|
Clearance following pulmonary administration (CL/F) (F= bioavailability) of tobramycin
Time Frame: One day
|
One day
|
Decrease of FEV1 in percentage measured by spirometry
Time Frame: One day
|
One day
|
Number of Participants with Adverse Events
Time Frame: One day
|
One day
|
Collaborators and Investigators
Investigators
- Principal Investigator: Huib Kerstjens, MD, PhD, University Medical Center Groningen
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Tobra-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchiectasis
-
Ruijin HospitalAstraZeneca Investment (China) Co., LtdNot yet recruitingBronchiectasis AdultChina
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Fondazione Policlinico Universitario Agostino Gemelli IRCCS; IRCCS Azienda... and other collaboratorsActive, not recruiting
-
University of Sao Paulo General HospitalEnrolling by invitation
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompletedBronchiectasis AdultBrazil
-
University of North Carolina, Chapel HillCompletedBronchiectasis AdultUnited States
-
Seoul National University Bundang HospitalUnknownSymptomatic BronchiectasisKorea, Republic of
-
Chang Gung Memorial HospitalNot yet recruitingBronchiectasis AdultTaiwan
-
Shanghai Pulmonary Hospital, Shanghai, ChinaNot yet recruitingBronchiectasis Adult
-
University of DundeeRecruitingBronchiectasis AdultUnited Kingdom
-
Papworth Hospital NHS Foundation TrustGlaxoSmithKlineCompletedBronchiectasis | Idiopathic BronchiectasisUnited Kingdom
Clinical Trials on Tobramycin
-
University of North Carolina, Chapel HillCystic Fibrosis FoundationCompletedCystic Fibrosis
-
Pari Pharma GmbHCompleted
-
Novartis PharmaceuticalsCompletedCystic FibrosisUnited States, Germany, United Kingdom, Colombia, Spain, France, Netherlands, Israel, Canada, Italy, Chile, Australia, Hungary, Mexico
-
FDA Office of Orphan Products DevelopmentCompletedCystic Fibrosis | Bacterial Infection
-
Chiesi Farmaceutici S.p.A.CompletedCystic FibrosisSpain, Ukraine, Czechia, France, Germany, Hungary, Poland, Russian Federation
-
Erik Allen JensenUniversity of FloridaActive, not recruiting
-
University of MilanChiesi Farmaceutici S.p.A.Completed
-
NovartisCompletedPseudomonas InfectionsGermany
-
National Institute of Diabetes and Digestive and...National Center for Research Resources (NCRR)CompletedCystic FibrosisUnited States
-
Novartis PharmaceuticalsCompletedCystic FibrosisSpain, Germany, Switzerland, United Kingdom, Ireland